IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.725
EU - Europa 14.360
AS - Asia 12.979
SA - Sud America 2.423
AF - Africa 1.033
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 20
Totale 57.570
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.636
SG - Singapore 7.615
RU - Federazione Russa 4.797
CN - Cina 3.543
IE - Irlanda 2.647
IT - Italia 2.633
UA - Ucraina 2.397
BR - Brasile 2.071
CA - Canada 923
CI - Costa d'Avorio 679
VN - Vietnam 569
SE - Svezia 338
GB - Regno Unito 328
DE - Germania 317
IN - India 297
KR - Corea 220
SN - Senegal 141
AR - Argentina 140
FI - Finlandia 120
PL - Polonia 117
NL - Olanda 113
FR - Francia 112
MX - Messico 112
JP - Giappone 94
BD - Bangladesh 91
CH - Svizzera 88
UZ - Uzbekistan 82
ZA - Sudafrica 80
AT - Austria 66
EC - Ecuador 66
TR - Turchia 65
IQ - Iraq 60
ES - Italia 58
HK - Hong Kong 53
CZ - Repubblica Ceca 50
BE - Belgio 47
GR - Grecia 44
ID - Indonesia 38
LB - Libano 37
MA - Marocco 36
CO - Colombia 35
VE - Venezuela 28
PK - Pakistan 27
IR - Iran 26
AU - Australia 21
CL - Cile 21
IL - Israele 21
PY - Paraguay 20
AE - Emirati Arabi Uniti 18
BJ - Benin 18
EU - Europa 18
SA - Arabia Saudita 18
JO - Giordania 17
EG - Egitto 16
KE - Kenya 16
PE - Perù 16
KZ - Kazakistan 15
LT - Lituania 15
BO - Bolivia 14
TN - Tunisia 14
BG - Bulgaria 13
DO - Repubblica Dominicana 12
NG - Nigeria 12
RS - Serbia 12
AZ - Azerbaigian 11
DZ - Algeria 10
NO - Norvegia 9
RO - Romania 9
UY - Uruguay 9
CR - Costa Rica 7
KW - Kuwait 7
MY - Malesia 7
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
AL - Albania 6
JM - Giamaica 6
NP - Nepal 6
OM - Oman 6
PA - Panama 6
TH - Thailandia 6
BH - Bahrain 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HN - Honduras 3
HU - Ungheria 3
LU - Lussemburgo 3
NI - Nicaragua 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
BY - Bielorussia 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
KG - Kirghizistan 2
LK - Sri Lanka 2
SR - Suriname 2
Totale 57.541
Salva come PNG Salva come JPEG
Città #
Dallas 5.122
Singapore 4.228
Santa Clara 2.904
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Moscow 1.970
Boardman 1.117
Ashburn 957
Chicago 957
Catania 908
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 651
Houston 515
Hefei 501
Los Angeles 446
Des Moines 423
Beijing 394
San Mateo 386
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
Saint Petersburg 182
Shenyang 180
São Paulo 180
Ho Chi Minh City 178
Hebei 176
Buffalo 166
New York 163
Jiaxing 148
Ottawa 148
Dakar 140
Changsha 135
Florence 135
Tianjin 110
Hanoi 106
Rome 104
Grafing 96
Council Bluffs 94
Kochi 92
Dong Ket 87
Milan 86
Tokyo 82
Warsaw 79
Brooklyn 75
Palermo 74
Montreal 71
Munich 71
Seattle 67
Rio de Janeiro 59
San Jose 59
Stockholm 58
Washington 58
Boston 57
Johannesburg 54
Orem 54
Denver 53
The Dalles 51
Hong Kong 50
San Francisco 49
Belo Horizonte 48
Poplar 48
Phoenix 47
Chennai 46
Columbus 46
Hangzhou 45
Redondo Beach 44
Brussels 42
Turku 42
London 41
Den Haag 39
Lappeenranta 39
Atlanta 38
Helsinki 38
Mexico City 37
Norwalk 37
Kunming 35
Mumbai 34
Falls Church 32
Pune 32
Tashkent 32
Ankara 31
Amsterdam 30
Curitiba 29
Jinan 29
Porto Alegre 29
Bremen 28
Bari 27
Brasília 27
Campinas 25
Guangzhou 25
Messina 25
Manchester 23
Brno 22
Guayaquil 22
Totale 38.469
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 271
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 266
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 208
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 200
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 197
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 190
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 176
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 175
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 164
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 162
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 159
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 159
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 158
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 157
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 157
Il Rasario. Semeiotica medica 156
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 151
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 150
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 148
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 147
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 146
Hedgehog signaling pathways in multiple myeloma 145
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 145
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 144
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 144
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 144
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 144
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 144
A snapshot of asparaginase-induced liver insufficiency. 141
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 140
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 140
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 139
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 138
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 137
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 137
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 136
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 136
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 135
A case of high-risk AML in a patient with advanced systemic mastocytosis 135
Acute pre-hepatic portal thrombosis: diagnosis and therapy 135
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 135
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 133
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 133
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 133
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 132
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 132
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 131
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 130
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 130
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 130
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 129
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 128
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 128
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 128
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 128
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 128
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 127
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 127
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 127
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 126
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 125
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 125
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 125
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 125
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 124
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 124
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 124
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 123
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 123
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 123
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 122
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 122
Bone turnover markers in patients with type 1 Gaucher disease 122
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 121
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 121
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 121
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 121
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 121
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 120
Acute myeloid leukemia in elderly patients. 119
Terapia del mieloma multiplo 117
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 117
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 117
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 117
Multiple Myeloma in 2023 Ways: From Trials to Real Life 115
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 115
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 115
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 115
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 115
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 114
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 114
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 113
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 113
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 113
Eventi avversi e trigger C12: Stroke in ospedale 113
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study 112
The Heme Oxygenase System in Hematological Malignancies 111
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 111
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 111
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 110
Totale 13.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 207.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 207.359
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.706 0 0 0 0 0 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202619.711 1.673 1.754 5.013 1.882 4.775 4.614 0 0 0 0 0 0
Totale 58.627